Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2014; 20(38): 13893-13898
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13893
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13893
Update on surgical treatment of pancreatic neuroendocrine neoplasms
Jan G D’Haese, Chiara Tosolini, Güralp O Ceyhan, Bo Kong, Christoph W Michalski, Jörg Kleeff, Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
Irene Esposito, Institute of Pathology, Technische Universität München, 81675 Munich, Germany
Author contributions: All authors contributed to the manuscript.
Correspondence to: Jörg Kleeff, MD, Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, 81675 Munich, Germany. kleeff@tum.de
Telephone: +49-89-41405098 Fax: +49-89-41405098
Received: March 5, 2014
Revised: May 7, 2014
Accepted: June 21, 2014
Published online: October 14, 2014
Processing time: 224 Days and 21.3 Hours
Revised: May 7, 2014
Accepted: June 21, 2014
Published online: October 14, 2014
Processing time: 224 Days and 21.3 Hours
Core Tip
Core tip: Surgical resection is the only curative treatment for pancreatic neuroendocrine neoplasms (PNENs). Surgical resection should be tailored and parenchyma-preserving whenever possible. Laparoscopic approaches are feasible and safe for pancreatic body and tail lesions. Regional lymph node dissection may prolong disease free survival. Cytoreductive surgery and palliative debulking (> 90%) of PNET liver metastases may extend survival. The most relevant prognostic factors are surgical intervention, tumor differentiation, patient age, and distant metastases.